» Articles » PMID: 36073646

Clinical Outcomes of Rhythm Control Strategies for Asymptomatic Atrial Fibrillation According to the Quality-of-Life Score: The CODE-AF (Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation) Registry

Overview
Date 2022 Sep 8
PMID 36073646
Authors
Affiliations
Soon will be listed here.
Abstract

Background Atrial fibrillation (AF) is associated with an increased risk of poor cardiovascular outcomes; appropriate rhythm control can reduce the incidence of these adverse events. Therefore, catheter ablation is recommended in symptomatic patients with AF. The aims of this study were to compare AF-related outcomes according to a baseline symptom scale score and to determine the best treatment strategy for asymptomatic patients with AF. Methods and Results This study enrolled all patients who completed a baseline Atrial Fibrillation Effect on Quality-of-Life (AFEQT) survey in a prospective observational registry. The patients were divided into 2 groups according to AFEQT score at baseline; scores ≤80 were defined as symptomatic, whereas scores >80 represented asymptomatic patients. The primary outcome was defined as a composite of hospitalization for heart failure, ischemic stroke, or cardiac death. This study included 1515 patients (mean age: 65.7±10.5 years; 998 [65.9%] men). The survival curve showed a poorer outcome in the symptomatic group compared with the asymptomatic group (log-rank =0.04). Rhythm control led to a significantly lower risk of a composite outcome in asymptomatic patients (hazard ratio [HR], 0.47 [95% CI, 0.27-0.84], =0.01). Rhythm control was associated with more favorable composite outcomes in the asymptomatic group with paroxysmal AF, left atrium diameter ≤50 mm, and CHADS-VASc score ≥3. Conclusions Symptomatic patients with AF experienced more adverse outcomes compared with asymptomatic patients. In asymptomatic patients with AF, a strategy of rhythm control improved the outcomes, especially with paroxysmal AF, smaller left atrium size, or higher stroke risk. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02786095.

Citing Articles

Identification and Functional Investigation of as a Novel Gene Underpinning Familial Atrial Fibrillation.

Jiang W, Sun Y, Qiu X, Wu S, Ding Y, Li N Diagnostics (Basel). 2024; 14(21).

PMID: 39518344 PMC: 11544904. DOI: 10.3390/diagnostics14212376.


2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E J Am Coll Cardiol. 2023; 83(1):109-279.

PMID: 38043043 PMC: 11104284. DOI: 10.1016/j.jacc.2023.08.017.


2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E Circulation. 2023; 149(1):e1-e156.

PMID: 38033089 PMC: 11095842. DOI: 10.1161/CIR.0000000000001193.


Comparison of the 11-Day Adhesive ECG Patch Monitor and 24-h Holter Tests to Assess the Response to Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation.

Kim S, Choi Y, Lee K, Kim S, Kim H, Shin S Diagnostics (Basel). 2023; 13(19).

PMID: 37835822 PMC: 10572592. DOI: 10.3390/diagnostics13193078.


Yield of diagnosis and risk of stroke with screening strategies for atrial fibrillation: a comprehensive review of current evidence.

Corica B, Bonini N, Imberti J, Romiti G, Vitolo M, Attanasio L Eur Heart J Open. 2023; 3(2):oead031.

PMID: 37051263 PMC: 10083691. DOI: 10.1093/ehjopen/oead031.

References
1.
Wallenhorst C, Martinez C, Freedman B . Risk of Ischemic Stroke in Asymptomatic Atrial Fibrillation Incidentally Detected in Primary Care Compared with Other Clinical Presentations. Thromb Haemost. 2021; 122(2):277-285. DOI: 10.1055/a-1541-3885. View

2.
Dries D, Exner D, Gersh B, Domanski M, Waclawiw M, Stevenson L . Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left.... J Am Coll Cardiol. 1998; 32(3):695-703. DOI: 10.1016/s0735-1097(98)00297-6. View

3.
Dorian P, Cvitkovic S, Kerr C, Crystal E, Gillis A, Guerra P . A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale. Can J Cardiol. 2006; 22(5):383-6. PMC: 2560532. DOI: 10.1016/s0828-282x(06)70922-9. View

4.
Andrade J, Wazni O, Kuniss M, Hawkins N, Deyell M, Chierchia G . Cryoballoon Ablation as Initial Treatment for Atrial Fibrillation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021; 78(9):914-930. DOI: 10.1016/j.jacc.2021.06.038. View

5.
Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O . Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012; 367(17):1587-95. DOI: 10.1056/NEJMoa1113566. View